Read this manager's filing book
Disclosed positions
SAMSARA BIOCAPITAL, LLC: source evidence dated 2026-08-15T03:59:59.999Z.
- Issuer
- SCHOLAR ROCK HLDG CORP
- Ticker
- SRRK
- Class
- COM
- Reported value
- $379,370,860
- Reported amount
- 6,897,652
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001744967-26-000010Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
Scroll sideways to compare all columns. Select a heading to sort.
| SCHOLAR ROCK HLDG CORP | SRRK | COM | $379,370,860 | 6,897,652 | SH | None |
| ALUMIS INC | ALMS | COM | $178,554,463 | 6,345,219 | SH | None |
| MINERALYS THERAPEUTICS INC | MLYS | COM | $158,400,066 | 5,871,018 | SH | None |
| SEPTERNA INC | SEPN | COM | $105,464,297 | 3,149,128 | SH | None |
| ALAMAR BIOSCIENCES INC | ALMR | COMMON STOCK | $67,191,598 | 2,480,310 | SH | None |
| NEUROGENE INC | NGNE | COM | $54,003,644 | 1,717,127 | SH | None |
| KALARIS THERAPEUTICS INC | KLRS | COM | $52,426,382 | 12,881,175 | SH | None |
| SPYGLASS PHARMA INC | SGP | COM SHS | $46,967,554 | 2,109,953 | SH | None |
| SUTRO BIOPHARMA INC | STRO | COM SHS | $35,287,350 | 1,062,872 | SH | None |
| INVENTIVA SA | IVA | ADS | $23,869,963 | 6,314,805 | SH | None |
| JADE BIOSCIENCES INC | JBIO | COM NEW | $16,359,186 | 736,237 | SH | None |
| PARABILIS MEDICINES INC | PBLS | COM | $15,218,924 | 556,044 | SH | None |
| VTV THERAPEUTICS INC | VTVT | CL A NEW | $11,238,374 | 298,496 | SH | None |
| AQUESTIVE THERAPEUTICS INC | AQST | COM | $10,400,000 | 2,500,000 | SH | None |
| NKARTA INC | NKTX | COM | $9,926,695 | 3,507,666 | SH | None |
| ARTIVA BIOTHERAPEUTICS INC | ARTV | COM | $9,262,152 | 954,861 | SH | None |
| RANI THERAPEUTICS HLDGS INC | RANI | COM CL A | $7,884,709 | 10,369,159 | SH | None |
| AGOMAB THERAPEUTICS NV | AGMB | SPONSORED ADS | $7,788,000 | 600,000 | SH | None |
| ABIVAX SA | ABVX | SPONSORED ADS | $7,341,960 | 55,095 | SH | None |
| X4 PHARMACEUTICALS INC | XFOR | COM NEW | $6,517,391 | 1,395,587 | SH | None |
| ELOXX PHARMACEUTICALS INC | ELOX | COM NEW | $5,552,000 | 400,000 | SH | None |
| COHERUS ONCOLOGY INC | CHRS | COM | $4,799,999 | 3,428,571 | SH | None |
| UPSTREAM BIO INC | UPB | COM | $2,447,722 | 353,717 | SH | None |
| GOSSAMER BIO INC | GOSS | COM | $1,188,833 | 7,222,559 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.